Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Benchtop Hematology Analyzer Enables Reduction of Manual Review Rates and Processes

By BiotechDaily International staff writers
Posted on 09 May 2013
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
A new benchtop hematology cellular analysis system provides laboratories with quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Building on its proven cellular analysis technology to further advance and optimize clinical diagnostic laboratories, Beckman Coulter Inc. (Pasadena, CA, USA) introduces the “UniCel DxH 600” Coulter cellular analysis system, a new benchtop hematology analyzer for mid- to high-volume laboratories. The hematology laboratory’s single most important step, and most time consuming, is the manual review. By reducing manual differential rates, the new analyzer frees labs to focus time on quickly and accurately reporting patient results, improving patient health, and reducing the overall cost of care.

With the same technology, user interface, and consumables as the UniCel DxH 800 Coulter analyzer, the UniCel DxH 600 brings superior standardization of results and process to the hematology laboratory, reducing personnel training and simplifying consumable inventory management. (To further enhance standardization, all new DxH 800 analyzers will be installed with the advanced software; and DxH 800 currently in use will be upgraded.)

The UniCel DxH 600 is equipped with robust software—recently cleared by the US Food and Drug Administration (FDA)—that provides new features, enhancements, and research-use parameters. This advanced software also saves time by allowing labs to partially release patient results manually or automatically via decision rules. It also offers users the ability to create and edit decision rules during instrument operation and offers predefined decision rules using Cell Population Data (for research use only; not for use in diagnostic procedures). Additional features include the ability to track workload by the day, hour, and test, as well as providing automatic notification of STAT samples that have not been processed or released within an expected time frame, helping users to report STAT results efficiently.

"This new hematology analyzer has the ability to transform the hematology lab with unparalleled efficiency, revolutionary scalability, and quality of results,” said John Blackwood, senior vice president, Product Management at Beckman Coulter Diagnostics; “The UniCel DxH 600 advances the technology that [...] will change how labs manage their cellular analysis process.”

Related Links:

Beckman Coulter




Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.